Cyclophosphamide in cardiac transplant recipients with frequent rejection: A six-year retrospective review

Clinical Transplantation

Volumn 10, Issue 5, 1996, Pages 437-443

  Wagoner, L E ^b,e   Taylor, D O ^a   Olsen, S L ^a   Bristow, M R ^c   O'Connell, J B ^d   Hammond, E H ^a   Lappe, D L ^a   Renlund, D G ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Allograft rejection; Cardiac transplantation; Cyclophosphamide; Immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; REVIEW;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 0029952790     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. CALABROSI P, CHABNER BA. Antineoplastic agents. In: GILMAN AG, RALL TW, NIES AS, AND TAYLOR P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon Press, 1990: 1209.
2. TURK JL, POLAK L, PARKER D. Control mechanisms in delayed-type hypersensitivity. Br Med Bull 1976: 32: 165.
3. CUPPS TR, EDGAR LC, FAVCI As. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982: 128: 2453.
4. ZHU LP, CUPPS TR, WHALEN G, FAVCI AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987: 79: 1082.
5. RATKOVEC R, HAMMOND EH, O'CONNELL JB, et al. Outcome of cardiac transplant recipients with a positive donor specific crossmatch: Preliminary results with plasmapheresis. Transplantation 1992: 54: 651.
6. WAGONER LE, OLSEN SL, BRISTOW MR, et al. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine induced hepatotoxicity. Transplantation 1993: 56: 1415.
7. BRISTOW MR, GILBERT EM, RENLUND DG, DEWITT CW, BURTON NA, O'CONNELL JB: Use of OKT3 monoclonal antibody in heart transplantation: review of the initial experience. J Heart Transpl 1988: 7: 1.
8. RENLUND DG, O'CONNELL JB, GILBERT EM, WATSON FS, BRISTOW MR. Feasibility of discontinuation of corticosteroid therapy in maintenance therapy in heart transplantation. J Heart Transplant 1987: 6: 71.
9. BILLINGHAM ME. Endomyocardial biopsy diagnosis of acute rejection in cardiac allografts. Progr Card Diseases 1990: 33: 11.
10. BILLINGHAM ME, CARY NRB, HAMMOND ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transpl 1990: 9: 587.
11. OLSEN SL, WAGONER LE, HAMMOND EH, TAYLOR DO, et al. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transpl 1993: 12: S135.
12. COSTANZO-NORDIN MR, SILVER MA, O'CONNELL JB, et al. Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 1987: 76 (suppl V): V-71.
13. HOSENPUD JD, HERSHBERGER RE, RATKOVEC RR, et al. Methotrexate for the treatment of patients with multiple episodes of acute cardiac allograft rejection. J Heart Lung Transpl 1992: 11: 739.
14. COSTANZO-NORDIN MR, GRUSK BB, SILVER MA, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation 1988: 78 (suppl III): III-47.
15. BOURGE RC, KIRKLIN JK, WHITE-WILLIAMS C, et al. Methotrexate pulse therapy in the treatment of recurrent acute heart rejection. J Heart Lung Transpl 1992: 11: 1116.
16. STARZL TE, PUTNAM CW, HALGRIMSON CG, et al. Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet 1971: 133: 981.
17. STARZL TE, GROTH CG, PUTNAN CW, et al. Cyclophosphamide for clinical renal and hepatic transplantation. Transpl Proc 1973: 5: 511.
18. STARZL TE, PUTNAM CW, HALGRIMSON CG, GROTH CG, BOOTH AS, PENN I. Renal transplantation under cyclophosphamide. Transpl Proc 1972: 4: 461.
19. JEFFERY JR, DOWNS AR, LYE C, RAMSEY E. Immunosuppression with azathioprine, prednisone, and cyclophosphamide. Transplantation 1979: 28: 10.
20. SOLLINGER HW, KALAYOGLU M, HOFFMAN RM, DEIERHOI MH, BELZER FO. Quadruple immunosuppressive therapy in whole pancreas transplantation. Transpl Proc 1987: 19: 2297.
21. FRASCA G, VANGELISTA A, DIFELICE A, et al. The rationale for plasmapheresis in renal graft rejection. Life Support Systems 1984: 2: 131.
22. CAVES PK, STINSON EB, DONG E, GRIEPP R, SHUMWAY NE, JULIAN DG. Proceedings: recent experience with human cardiac transplantation. Br Heart J 1974: 36: 1036.
23. ULDALL R, TAYLOR R, SWINNEY J. Cyclophosphamide in human organ transplantation. Lancet 1971: 2: 258.
24. BERLYNE GM, DANOVITCH GM. Cyclophosphamide for immunosuppression in renal transplantation. Lancet 1971: 2:924.
25. TAYLOR DO, BRISTOW MR, O'CONNELL JB, et al. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: Decreased sensitization to OKT3. Transplantation 1994: 58: 645.